Rashad Nawfal

Dr. Rashad Nawfal

Dana-Farber Cancer Institute, Boston, Massachusetts, USA
+2
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 February 2022 in Irish Journal of Medical Science (1971 -)
Verified
Journal Article
Closed access
PDF file
DJDiana Georges Jabbour
Diana Georges Jabbour
JMJad El Masri
Jad El Masri
Rashad NawfalRashad Nawfal
Rashad Nawfal
DMDiana Malaeb
Diana Malaeb
PSPascale Salameh
Pascale Salameh

23 April 2022 in Cancers
Verified
Journal Article
Open access
PDF file
TZTalal El Zarif
Talal El Zarif
MYMarcel Yibirin
Marcel Yibirin
DGDiana Carolina De Oliveira Gomes
Diana Carolina De Oliveira Gomes
MMMarc Machaalani
Marc Machaalani
Rashad NawfalRashad Nawfal
Rashad Nawfal
NBNizar Bitar
Nizar Bitar
Colorectal cancer (CRC) is the third most common cancer in the world. Despite improvement in standardized screening methods and the development of promising therapies, the 5-year survival rates are as low as 10% in the metastatic setting. The increasing life expectancy of the general population, higher rates of obesity, poor diet, and comorbidities contribute to the increasing trends in incidence. Drug repurposing offers an affordable solution to achieve new indications for previously approved drugs that could play a protagonist or adjuvant role in the treatment of CRC with the advantage of treating underlying comorbidities and decreasing chemotherapy toxicity. This review elaborates on the current data that supports drug repurposing as a feasible option for patients with CRC with a focus on the evidence and mechanism of action promising repurposed candidates that are widely used, including but not limited to anti-malarial, anti-helminthic, anti-inflammatory, anti-hypertensive, anti-hyperlipidemic, and anti-diabetic agents.

30 August 2022 in Cellular and Molecular Life Sciences
Verified
Journal Article
Closed access
PDF file
MNMohamed Noureldein
Mohamed Noureldein
Rashad NawfalRashad Nawfal
Rashad Nawfal
SBSara Bitar
Sara Bitar
SMScott S. Maxwell
Scott S. Maxwell
IKIshant Khurana
Ishant Khurana
AEAssaad Eid
Assaad Eid

16 March 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
BDBatoul Dia
Batoul Dia
SASahar Alkhansa
Sahar Alkhansa
RNRachel Njeim
Rachel Njeim
SMSarah Al Moussawi
Sarah Al Moussawi
TFTheresa Farhat
Theresa Farhat
AEAssaad Eid
Assaad Eid
Diabetic kidney disease (DKD) is a serious complication of diabetes, affecting millions of people worldwide. Inflammation and oxidative stress are key contributors to the development and progression of DKD, making them potential targets for therapeutic interventions. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have emerged as a promising class of drugs, with evidence demonstrating that they can improve renal outcomes in people with diabetes. However, the exact mechanism by which SGLT2i exert their renoprotective effects is not yet fully understood. This study demonstrates that dapagliflozin treatment attenuates renal injury observed in type 2 diabetic mice. This is evidenced by the reduction in renal hypertrophy and proteinuria. Furthermore, dapagliflozin decreases tubulointerstitial fibrosis and glomerulosclerosis by mitigating the generation of reactive oxygen species and inflammation, which are activated through the production of CYP4A-induced 20-HETE. Our findings provide insights onto a novel mechanistic pathway by which SGLT2i exerts their renoprotective effects. Overall, and to our knowledge, the study provides critical insights into the pathophysiology of DKD and represents an important step towards improving outcomes for people with this devastating condition.

10 August 2025 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
CLChris Labaki
Chris Labaki
ESEddy Saad
Eddy Saad
KMKatrine N. Madsen
Katrine N. Madsen
CHCharbel Hobeika
Charbel Hobeika
KBKevin Bi
Kevin Bi
DBDavid A. Braun
David A. Braun
PURPOSE: While immune checkpoint inhibition (ICI) has transformed the management of many advanced renal cell carcinomas (RCCs), the determinants of effective antitumor immunity for chromophobe RCC (ChRCC) and renal oncocytic tumors remain an unmet clinical and scientific need. METHODS: Single-cell transcriptomic and T-cell receptor profiling was performed on tumor and adjacent normal tissue of patients with ChRCC and renal oncocytic neoplasms. Using machine learning, the cellular origin of renal oncocytic neoplasms was evaluated, with analysis of associated oncogenic pathways. Using immunohistochemistry, immune infiltration was analyzed in renal oncocytic neoplasms in comparison with clear cell RCC (ccRCC). Immune checkpoint expression, clonal expansion, and tumor specificity were compared between ChRCC and ccRCC. Using the International Metastatic RCC Database Consortium data set, clinical outcomes of patients with metastatic ChRCC (mChRCC) treated with first-line systemic regimens were compared with those of patients with ccRCC. RESULTS: We validated α-intercalated cells as the cellular origin of renal oncocytic neoplasms. We identified a downregulation of HLA class I molecules with enrichment of potentially targetable pathways including mammalian target of rapamycin and ferroptosis in ChRCC. The tumor microenvironment of ChRCC showed markedly decreased immune infiltration, with a pronounced depletion in tumor-infiltrating CD8 + T cells. ChRCC-infiltrating CD8 + T cells demonstrated lower immune checkpoint expression, diminished clonal expansion, and decreased tumor specificity. Clinical analysis identified poor survival outcomes selectively among patients with mChRCC treated with immune-based therapies. CONCLUSION: Immunogenomic analysis of ChRCC revealed profound depletion of T cells, with an immune phenotype marked by a lack of expression of immune checkpoints and poor tumor specificity, suggesting that the few T cells in these tumor types are likely nonspecific bystanders. This immune-cold environment hinders an effective response to immunotherapy and underscores the need for ChRCC-tailored treatments designed to improve tumor-specific T-cell infiltration into the microenvironment.

26 August 2024 in The Oncologist
Verified
Journal Article
Open access
PDF file
MMMarc Machaalani
Marc Machaalani
MEMarc Eid
Marc Eid
KSKarl Semaan
Karl Semaan
RCRazane El Hajj Chehade
Razane El Hajj Chehade
Rashad NawfalRashad Nawfal
Rashad Nawfal
TCToni K Choueiri
Toni K Choueiri
Liquid biopsy has emerged as a powerful, noninvasive tool for the detection and monitoring of cancer. It relies on identifying tumor markers, such as circulating tumor cells (CTCs), cell-free tumor DNA (ctDNA), cell-free RNA (cfRNA), exosomes, as well as tumor-derived metabolites and proteins in biofluids.1 Prior studies in individuals with renal cell carcinoma (RCC) have reported negative correlations between ctDNA levels and clinical outcomes, including cancer-specific survival,2 progression-free survival (PFS),2,3 and overall survival (OS).3 In this issue of The Oncologist, Correa et al build upon these foundations using a bespoke whole-exome sequencing (WES)-informed ctDNA assay (Signatera RUO, Natera, Inc.), demonstrating its prognostic value for RCC recurrence in patients who underwent nephrectomy.4 The authors conducted deep WES on formalin-fixed, paraffin-embedded (FFPE) tumor samples and matched normal blood samples from 45 patients to identify somatic single nucleotide variants present in the tumor but not in germline DNA. By assaying cell-free DNA for these patient-specific, bespoke panel of mutations, the authors detected ctDNA in 18 of 36 (50%) patients tested preoperatively and in 12 of 45 (27%) after nephrectomy. Preoperative ctDNA detection was not correlated with disease grade but was associated with a larger primary tumor. The authors showed that the pre- and post-operative detection of ctDNA was significantly associated with a shorter recurrence-free survival (hazard ratio (HR) 2.7, P = 0.046 and HR 3.23, P = 0.003, respectively). These findings represent a step toward guiding the use of adjuvant therapies in patients who are at high risk of relapse or not cured by nephrectomy based on ctDNA levels. However, despite employing a bespoke approach optimized for sensitivity, the ability to detect ctDNA was limited. Only 27% (12 of 45) of patients had ctDNA detected at any time after surgery in a population that ended up with a 60% rate (27 of 45) of established recurrences. A warranted question thus emerges: could emerging liquid biopsy technologies improve sensitivity by looking beyond somatic mutations?